Hippocampal pyramidal cells (PCs) express many GABAAR subunit types and receive GABAergic inputs from distinct interneurons. Previous experiments revealed input-specific differences in α1 and α2 subunit densities in perisomatic synapses, suggesting distinct IPSC decay kinetics. However, IPSC decays evoked by axo-axonic, parvalbumin- or cholecystokinin-expressing basket cells were found to be similar. Using replica immunogold labeling, here we show that all CA1 PC somatic and AIS synapses contain the α1, α2, β1, β2, β3 and γ2 subunits. In CA3 PCs, 90% of the perisomatic synapses are immunopositive for the α1 subunit and all synapses are positive for the remaining five subunits. Somatic synapses form unimodal distributions based on their immunoreactivity for these subunits. The α2 subunit densities in somatic synapses facing Cav2.1 (i.e. parvalbumin) or Cav2.2 (cholecystokinin) positive presynaptic active zones are comparable. We conclude that perisomatic synapses made by three distinct interneuron types have similar GABAA receptor subunit content.
Pubmed ID: 27537197 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A national mouse monoclonal antibody generating resource for biochemical and immunohistochemical applications in mammalian brain. NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the initial NeuroMab screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e. NeuroMabs): for immunocytochemical-based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks. The NeuroMab facility was initially funded with a five-year U24 cooperative grant from NINDS and NIMH. The initial goal of the facility for this funding period is to generate a library of novel NeuroMabs against neuronal proteins, initially focusing on membrane proteins (receptors/channels/transporters), synaptic proteins, other neuronal signaling molecules, and proteins with established links to disease states. The scope of the facility was expanded with supplements from the NIH Blueprint for Neuroscience Research to include neurodevelopmental targets, the NIH Roadmap for Medical Research to include epigenetics targets, and NIH Office of Rare Diseases Research to include rare disease targets. These NeuroMabs will then be produced on a large scale and made available to the neuroscience research community on an inexpensive basis as tissue culture supernatants or purified immunoglobulin by Antibodies Inc. The UC Davis/NIH NeuroMab Facility makes NeuroMabs available directly to end users and is unable to accommodate sales to distributors for third party distribution. Note, NeuroMab antibodies are now offered through antibodiesinc.
View all literature mentionsThis polyclonal targets mouse parvalbumin (NM013645)
View all literature mentionsThis monoclonal targets GABA-A receptor gamma2
View all literature mentionsThis polyclonal targets Ca2+ channel (N-type, alpha-1B subunit)
View all literature mentionsThis polyclonal targets Ca2+ channel (P/Q-type, alpha-1A subunit)
View all literature mentionsThis polyclonal targets Neuroligin 2
View all literature mentionsThis polyclonal targets GABA-A receptor gamma2
View all literature mentionsThis polyclonal targets GABA-A receptor gamma2
View all literature mentionsThis polyclonal targets GABA-A receptor beta3
View all literature mentionsThis polyclonal targets GABA-A receptor beta2
View all literature mentionsThis polyclonal targets GABA-A receptor beta2
View all literature mentionsThis polyclonal targets GABA-A receptor beta1
View all literature mentionsThis polyclonal targets GABA-A receptor beta1
View all literature mentionsThis polyclonal targets GABA-A receptor alpha2
View all literature mentionsThis monoclonal targets GABA-A receptor alpha1
View all literature mentionsThis unknown targets NaV1.6 (SCN8A) Channel
View all literature mentionsThis monoclonal targets Ankyrin-G (Staining)
View all literature mentionsThis polyclonal targets mouse Nlgn2, 732-761 aa (NM_198862)
View all literature mentionsThis monoclonal targets GABA(A)R, Beta3
View all literature mentionsThis monoclonal targets Ankyrin-G (Staining)
View all literature mentionsThis polyclonal targets mouse Nlgn2, 732-761 aa (NM_198862)
View all literature mentionsThis unknown targets NaV1.6 (SCN8A) Channel
View all literature mentionsThis monoclonal targets GABA(A)R, Beta3
View all literature mentionsThis unknown targets NaV1.6 (SCN8A) Channel
View all literature mentionsThis monoclonal targets Ankyrin-G (Staining)
View all literature mentionsThis polyclonal targets mouse Nlgn2, 732-761 aa (NM_198862)
View all literature mentionsThis monoclonal targets GABA(A)R, Beta3
View all literature mentions